ELI LILLY AND COMPANY Inventory Write-down
ELI LILLY AND COMPANY (LLY) reported Inventory Write-down of $339.70 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2024-02-21
- ELI LILLY AND COMPANY inventory write-down for the quarter ending 2021-12-31 was -$95.40M.
- ELI LILLY AND COMPANY inventory write-down for the quarter ending 2021-09-30 was -$69.40M.
- ELI LILLY AND COMPANY inventory write-down for the quarter ending 2021-06-30 was $423.00M.
- ELI LILLY AND COMPANY inventory write-down for fiscal 2021 was $339.70M.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$95.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$164.80M derived: sum of 2 quarters · filed 2024-02-21 | $258.20M derived: sum of 3 quarters · filed 2024-02-21 | $339.70M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$69.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $353.60M derived: sum of 2 quarters · filed 2022-11-01 | $435.10M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $423.00M 10-Q · filed 2022-08-04 | $504.50M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |